✦ LIBER ✦

Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease

✍ Scribed by K. Ahmadi-Simab; B. Hellmich; W. L. Gross

Book ID: 108711443
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 118 KB
Volume: 36
Category: Article
ISSN: 0014-2972
DOI: 10.1111/j.1365-2362.2006.01695.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Systemic sclerosis–related pulmonary hyp

Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies

✍ Jérôme Le Pavec; Reda E. Girgis; Noah Lechtzin; Stephen C. Mathai; David Launay; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Pulmonary arterial hypertension is a maj

Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease

✍ Salim Trad; Zahir Amoura; Catherine Beigelman; Julien Haroche; Nathalie Costedoa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

Defining appropriate outcome measures in

Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis

✍ Distler, Oliver ;Behrens, Frank ;Pittrow, David ;Huscher, Doerte ;Denton, Christ 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 566 KB

Initial experience with bosentan (Tracle

Initial experience with bosentan (Tracleer®) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children

✍ Gilbert, N. ;Luther, Y.-C. ;Miera, O. ;Nagdyman, N. ;Ewert, P. ;Berger, F. ;Lang 📂 Article 📅 2005 🏛 Springer 🌐 German ⚖ 205 KB